MUNICH, May 07, 2026 – BONVENTURE is participating in the current growth financing round of Vivira Health Lab, one of Germany’s leading digital health companies in the field of musculoskeletal care. BONVENTURE has already been invested in the company since 2024 and is continuing its commitment with this renewed investment. Vivira successfully integrates digital therapy into the day-to-day operations of outpatient medical practices, thereby making an important contribution to closing existing gaps in healthcare provision. Existing investors are also participating in the financing round.
Epidemic of back pain: When help is hard to reach
Back pain, tense shoulders or limited mobility: For millions of people in Germany, musculoskeletal complaints have long been part of everyday life. What often starts as a seemingly minor restriction can quickly lead to longer absences, chronic issues and a noticeable loss of quality of life. At the same time, access to fast, appropriate and reliable therapy remains difficult for many affected individuals; nowhere is the shortage of skilled workers as great as in physiotherapy. This is exactly where our portfolio company Vivira comes in.
Angela Lawaldt, Partner at BONVENTURE, says:
“We invest in health technologies that create measurable – and in this case tangible – improvements for patients. That’s exactly what Vivira does. The simple, free DiGA therapy for home use is an effective approach to tackling the widespread problem of musculoskeletal disorders. With our participation, we want to help Vivira further improve healthcare delivery and reach more people.”
The new financing round is intended at its core to further expand needs-based Vivira care, approve additional therapies, and develop new digital health services for musculoskeletal health. A key focus is on the use of artificial intelligence. In the future, it will help further improve therapy success and deploy medical data in a legally compliant manner more targeted and efficient for the benefit of patients. This represents an important step toward even more precise, patient-centered, and scalable care.
Musculoskeletal disorders are among the most common health burdens in Germany. Back pain is one of the main causes of work incapacity and early retirement. At the same time, physiotherapy care is strained in many places: appointments are scarce, waiting times long, and not everyone receives the treatment they need. For many patients, this means complaints remain untreated for too long or are only inadequately addressed, which in turn worsens the pain. Vivira addresses this reality with clinically validated digital movement therapies for home use and thus offers an innovative complement to conventional physiotherapy.
The use is uncomplicated for patients: The costs are covered by all statutory health insurance funds and many private health insurance companies. All doctors in Germany can prescribe Vivira; this way, digital therapy is not intended as a special or substitute solution, but as part of a care that actually reaches everyday life and can have an effect there.
Dr. Philip Heimann, Co-Founder & CEO at Vivira, adds:
“The demand for digital therapy solutions is enormous, while significant care gaps persist and the extent of under-supply is huge. (…) With this investment, we are accelerating our growth, reaching more patients, and further developing evidence-based, AI-supported therapies – with clear therapeutic authority remaining with doctors. With the investment, we are accelerating our growth, treating even more patients, and bringing additional therapy solutions into the healthcare system.”